Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients

Journal of Viral Hepatitis

Volumn 18, Issue 10, 2011, Pages

  Gramenzi, A ^a   Loggi, E ^a   Micco, L ^a   Cursaro, C ^a   Fiorino, S ^a   Galli, S ^a   Gitto, S ^a   Galli, C ^b   Furlini, G ^a   Bernardi, M ^a   Andreone, P ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b ABBOTT DIAGNOSTICS   (Italy)

Author keywords

antigen quantification; hepatitis B virus; nucleos(t)ide analogues; treatment; virological resistance

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS E ANTIGEN; LAMIVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; LONG TERM CARE; MALE; MONOTHERAPY; OPEN STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG MONITORING; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; SERUM; TREATMENT OUTCOME;

EID: 80052837790     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01473.x     Document Type: Article

References (21)

1. Laras A, Koskinas J, Dimou E, Kostamena A, Hadziyannis SJ,. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 2006; 44: 694-702. (Pubitemid 44433726)
2. Feld JJ, Wong DKH, Heathcote EJ,. Endpoints of therapy in chronic hepatitis B. Hepatology 2009; 49: S96-S102.
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
4. Dusheiko G, Antonakopoulos N,. Current treatment of hepatitis B. Gut 2008; 57: 105-124.
5. Andersson KL, Chung T,. Monitoring during and after antiviral therapy for hepatitis B. Hepatology 2009; 49: S166-S173.
6. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-684. (Pubitemid 44433724)
7. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462-1468. (Pubitemid 350181604)
8. Galli C, Orlandini E, Penzo L, et al. What is the role of serology for the study of chronic hepatitis B virus infection in the age of molecular biology? J Med Virol 2008; 80: 974-979. (Pubitemid 351657007)
9. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-1758. (Pubitemid 38736340)
10. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-1157.
11. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-1150.
12. Moucari R, Korevaar A, Lada O, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009; 50: 1084-1092.
13. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ,. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 73-82. (Pubitemid 46340428)
14. Kohmoto M, Enomoto M, Tamori A, et al. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol 2005; 75: 235-239. (Pubitemid 40053734)
15. Borgniet O, Parvaz P, Bouix C, et al. Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B. J Med Virol 2009; 81: 1336-1342.
16. Deguchi M, Yamashita N, Kagita M, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004; 115: 217-222. (Pubitemid 37506037)
17. Rodella A, Galli C, Terlenghi L, Perandin F, Bonfanti C, Manca N,. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol 2006; 37: 206-212. (Pubitemid 44559777)
18. Zoulim F, Perrillo R,. Hepatitis B. Reflections on the current approach to antiviral therapy. J Hepatol 2008; 48: S2-S19.
19. Moucari R, Lada O, Marcellin P,. Chronic hepatitis B: back to the future with HBsAg. Expert Rev Anti Infect Ther 2009; 7: 633-636.
20. Brunetto MR,. A new role for an old marker, HBsAg. J Hepatol 2010; 52: 475-477.
21. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M,. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-1661. (Pubitemid 26001954)